Name | Number of supported studies | Average coverage | |
---|---|---|---|
fibroblast | 20 studies | 35% ± 12% | |
endothelial cell | 18 studies | 34% ± 14% | |
basal cell | 18 studies | 42% ± 24% | |
pericyte | 17 studies | 31% ± 13% | |
smooth muscle cell | 14 studies | 33% ± 12% | |
epithelial cell | 12 studies | 52% ± 24% | |
regulatory T cell | 11 studies | 23% ± 7% | |
dendritic cell | 10 studies | 29% ± 11% | |
endothelial cell of vascular tree | 10 studies | 37% ± 15% | |
epithelial cell of proximal tubule | 8 studies | 27% ± 7% | |
ciliated cell | 8 studies | 39% ± 20% | |
T cell | 7 studies | 27% ± 9% | |
platelet | 7 studies | 24% ± 6% | |
myofibroblast cell | 7 studies | 24% ± 8% | |
secretory cell | 7 studies | 56% ± 19% | |
connective tissue cell | 6 studies | 27% ± 7% | |
endothelial cell of lymphatic vessel | 5 studies | 37% ± 17% | |
endothelial cell of artery | 5 studies | 25% ± 13% | |
abnormal cell | 5 studies | 32% ± 12% | |
vein endothelial cell | 5 studies | 25% ± 8% | |
plasma cell | 4 studies | 33% ± 9% | |
pancreatic A cell | 4 studies | 34% ± 5% | |
kidney loop of Henle epithelial cell | 4 studies | 27% ± 11% | |
brush cell | 4 studies | 35% ± 16% | |
pro-B cell | 4 studies | 28% ± 3% | |
leukocyte | 4 studies | 26% ± 6% | |
mast cell | 3 studies | 17% ± 1% | |
natural killer cell | 3 studies | 22% ± 1% | |
type I pneumocyte | 3 studies | 18% ± 2% | |
squamous epithelial cell | 3 studies | 36% ± 24% | |
mononuclear phagocyte | 3 studies | 22% ± 5% | |
effector memory CD8-positive, alpha-beta T cell | 3 studies | 21% ± 2% | |
podocyte | 3 studies | 67% ± 14% | |
myeloid cell | 3 studies | 23% ± 6% | |
enterocyte | 3 studies | 22% ± 7% | |
CD8-positive, alpha-beta T cell | 3 studies | 17% ± 1% | |
gamma-delta T cell | 3 studies | 33% ± 10% | |
luminal cell of prostate epithelium | 3 studies | 46% ± 4% | |
pancreatic ductal cell | 3 studies | 43% ± 11% | |
enteroendocrine cell | 3 studies | 24% ± 5% | |
keratinocyte | 3 studies | 32% ± 8% | |
hematopoietic stem cell | 3 studies | 23% ± 4% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 8 studies | 29% ± 16% | |
uterus | 5 studies | 31% ± 14% | |
pancreas | 4 studies | 31% ± 5% | |
intestine | 4 studies | 21% ± 5% | |
kidney | 3 studies | 23% ± 2% | |
placenta | 3 studies | 19% ± 5% | |
eye | 3 studies | 32% ± 12% | |
lymph node | 3 studies | 23% ± 6% | |
breast | 3 studies | 35% ± 11% | |
prostate | 3 studies | 66% ± 11% | |
liver | 3 studies | 26% ± 12% | |
skin | 3 studies | 28% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
kidney | 100% | 8444.36 | 89 / 89 | 99% | 94.12 | 893 / 901 |
bladder | 100% | 3222.52 | 21 / 21 | 97% | 77.48 | 489 / 504 |
thymus | 98% | 3674.87 | 641 / 653 | 99% | 116.81 | 598 / 605 |
lung | 98% | 4847.96 | 567 / 578 | 97% | 72.25 | 1122 / 1155 |
uterus | 96% | 3998.15 | 163 / 170 | 99% | 110.04 | 455 / 459 |
breast | 100% | 5785.34 | 458 / 459 | 92% | 44.93 | 1024 / 1118 |
stomach | 92% | 2591.43 | 329 / 359 | 98% | 43.54 | 281 / 286 |
ovary | 91% | 3224.02 | 164 / 180 | 98% | 63.47 | 422 / 430 |
skin | 97% | 3718.54 | 1748 / 1809 | 93% | 51.52 | 437 / 472 |
esophagus | 89% | 2029.98 | 1293 / 1445 | 98% | 49.42 | 180 / 183 |
liver | 90% | 3252.33 | 203 / 226 | 98% | 88.48 | 397 / 406 |
intestine | 75% | 1612.97 | 723 / 966 | 96% | 46.02 | 508 / 527 |
prostate | 76% | 1670.35 | 186 / 245 | 83% | 29.93 | 418 / 502 |
brain | 55% | 1474.77 | 1452 / 2642 | 97% | 101.57 | 683 / 705 |
adrenal gland | 34% | 645.08 | 89 / 258 | 83% | 36.25 | 192 / 230 |
pancreas | 13% | 179.84 | 43 / 328 | 98% | 73.37 | 174 / 178 |
blood vessel | 100% | 11149.48 | 1335 / 1335 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 81.42 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 28.34 | 1 / 1 |
adipose | 100% | 7540.51 | 1200 / 1204 | 0% | 0 | 0 / 0 |
muscle | 91% | 9358.42 | 734 / 803 | 0% | 0 | 0 / 0 |
spleen | 85% | 1806.52 | 206 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 82% | 3152.45 | 760 / 929 | 0% | 0 | 0 / 0 |
heart | 80% | 2177.31 | 691 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 76% | 22.30 | 22 / 29 |
eye | 0% | 0 | 0 / 0 | 55% | 19.60 | 44 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0033140 | Biological process | negative regulation of peptidyl-serine phosphorylation of STAT protein |
GO_0006281 | Biological process | DNA repair |
GO_0071260 | Biological process | cellular response to mechanical stimulus |
GO_0046330 | Biological process | positive regulation of JNK cascade |
GO_0000079 | Biological process | regulation of cyclin-dependent protein serine/threonine kinase activity |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_1900745 | Biological process | positive regulation of p38MAPK cascade |
GO_0043537 | Biological process | negative regulation of blood vessel endothelial cell migration |
GO_0007098 | Biological process | centrosome cycle |
GO_0016525 | Biological process | negative regulation of angiogenesis |
GO_2000379 | Biological process | positive regulation of reactive oxygen species metabolic process |
GO_0006915 | Biological process | apoptotic process |
GO_0071479 | Biological process | cellular response to ionizing radiation |
GO_0043065 | Biological process | positive regulation of apoptotic process |
GO_0042770 | Biological process | signal transduction in response to DNA damage |
GO_0051726 | Biological process | regulation of cell cycle |
GO_0071901 | Biological process | negative regulation of protein serine/threonine kinase activity |
GO_0016607 | Cellular component | nuclear speck |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0042803 | Molecular function | protein homodimerization activity |
GO_1990841 | Molecular function | promoter-specific chromatin binding |
GO_0019900 | Molecular function | kinase binding |
GO_0046982 | Molecular function | protein heterodimerization activity |
GO_0005515 | Molecular function | protein binding |
Gene name | GADD45A |
Protein name | Growth arrest and DNA damage inducible alpha Growth arrest and DNA damage-inducible protein GADD45 alpha Growth arrest and DNA damage-inducible protein GADD45 alpha (DNA damage-inducible transcript 1 protein) (DDIT-1) Growth arrest and DNA damage inducible alpha (Growth arrest and DNA-damage-inducible 45 alpha) |
Synonyms | GADD45 DDIT1 |
Description | FUNCTION: In T-cells, functions as a regulator of p38 MAPKs by inhibiting p88 phosphorylation and activity (By similarity). Might affect PCNA interaction with some CDK (cell division protein kinase) complexes; stimulates DNA excision repair in vitro and inhibits entry of cells into S phase. . |
Accessions | ENST00000617962.2 A0A087WZQ0 P24522 A0A3B3ITF9 ENST00000650283.1 ENST00000370985.4 [P24522-2] ENST00000370986.9 [P24522-1] ENST00000648742.1 A5JUZ3 |